Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-05-2023 | Multiple Myeloma | Case report

Lenalidomide

Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis: case report

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Yoshida M, et al. Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma. International Journal of Hematology 117 : 769-773, No. 5, Dec 2022. Available from: URL: http://doi.org/10.1007/s12185-022-03499-2 Yoshida M, et al. Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma. International Journal of Hematology 117 : 769-773, No. 5, Dec 2022. Available from: URL: http://​doi.​org/​10.​1007/​s12185-022-03499-2
Metadata
Title
Lenalidomide
Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis: case report
Publication date
01-05-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-39455-z

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Ajmaline

Case report

Ceftriaxone

Case report

Ipilimumab

Case report

Icotinib misuse

Case report

Cetuximab